Oncology (Williston Park). 2019 Oct 28;33(10):686509.
Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach.
转移性前列腺癌仍然是一种危及生命的疾病；尽管我们在构成管理基础的系统方法方面取得了重大进展，但尚未存在治愈范例。立体定向消融放疗 (SABR) 的转移导向治疗 (MDT) 已成为治疗低容量转移性前列腺癌的一种有前途的补充技术。本文将回顾这种方法的原理、潜在益处和实际考虑因素。
